Page 112 - 202012

tients with chronic kidney disease[J]. Herz，2020，45（2）： safety of low-dose aspirin in chronic kidney disease[J].
122-128. Am J Kid Dis，2005，45（3）：473-484.
[ 5 ] NAGAI K，YAMAGATA K，OHKUBO R，et al. Annual [17] LEVEY AS，BOSCH JP，LEWIS JB，et al. A more accu-
decline in estimated glomerular filtration rate is a risk fac- rate method to estimate glomerular filtration rate from se-
tor for cardiovascular events independent of protein- rum creatinine：a new prediction equation：modification
uria[J]. Nephrology，2014，19（9）：574-580. of diet in renal disease study group[J]. Ann Intern Med，
[ 6 ] PERKOVIC V，VERDON C，NINOMIYA T，et al. The re- 1999，130（6）：461-470.
lationship between proteinuria and coronary risk：a sys- [18] K/DOQI Work Group. K/DOQI clinical practice guide-
tematic review and meta-analysis[J]. PLoS Med，2008. lines for cardiovascular disease in dialysis patients[J]. Am
DOI：10.1371/journal.pmed.0050207. J Kidney Dis，2005，45（Suppl 3）：S1-S153.
[ 7 ] 李轲，马爱霞.我国应用阿司匹林进行心血管疾病一级预 [19] BIBBINS-DOMINGO K，U.S. Preventive Services Task
防的药物经济学评价[J].中国药房，2018，29（24）：3411- Force. Aspirin use for the primary prevention of cardiovas-
3416. cular disease and colorectal cancer：U.S. preventive servic-
[ 8 ] GOWDA SN，BEL M，JAHRAUS M，et al. Aspirin in pri- es task force recommendation statement[J]. Ann Intern
mary and secondary prevention of cardiovascular dis- Med，2016，164（12）：836-845.
ease[J]. S D Med，2020，73（3）：130-135. [20] 张晓娟，梁庆娜，金惠敏.小剂量阿司匹林预防慢性肾脏
[ 9 ] MATHEW RO，BANGALORE S，LAVELLE MP，et al. 病患者心血管事件的研究进展[J].中国血液净化，2017，
Diagnosis and management of atherosclerotic cardiovascu- 16（8）：558-561.
lar disease in chronic kidney disease：a review[J]. Kidney [21] SUTCLIFFE P，CONNOCK M，GURUNG T，et al. Aspi-
Int，2017，91（4）：797-807. rin for prophylactic use in the primary prevention of car-
[10] 刘千红，侯亮，姚树青.小剂量阿司匹林用于慢性肾脏病 diovascular disease and cancer：a systematic review and
患者的效果观察[J].疑难病杂志，2012，11（6）：422-424. overview of reviews[J]. Health Technol Asses，2013，17
[11] GOICOECHEA M，DE VINUESA SG，QUIROGA B， （43）：251-253.
et al. Aspirin for primary prevention of cardiovascular dis- [22] PALMER SC，DI MICCO L，RAZAVIAN M，et al. Ef-
ease and renal disease progression in chronic kidney dis- fects of antiplatelet therapy on mortality and cardiovascu-
ease patients：a multicenter randomized clinical trial lar and bleeding outcomes in persons with chronic kidney
（AASER study）[J]. Cardiovasc Drugs Ther，2018，32 disease：a systematic review and meta-analysis[J]. Ann In-
（3）：255-263. tern Med，2012，156（6）：445-459.
[12] HIGGINS JP，ALTMAN DG，GØTZSCHE PC，et al. The [23] KIM AJ，LIM HJ，RO H，et al. Low-dose aspirin for pre-
cochrane collaboration’s tool for assessing risk of bias in vention of cardiovascular disease in patients with chronic
randomised trials[J]. BMJ，2011. DOI：10.1136/bmj.d5928. kidney disease[J]. PLoS One，2014.DOI：10.1371/journal.
[13] LAU J，IOANNIDIS JP，SCHMID CH. Quantitative syn- pone.0104179.
thesis in systematic reviews[J]. Ann Intern Med，1997，127 [24] AMETT DK，BLUMENTHAL RS，ALBERT MA，et al.
（9）：820-826. 2019 ACC/AHA guideline on the primary prevention of
[14] SAITO Y，MORIMOTO T，OGAWA H，et al. Low-dose cardiovascular disease：executive summary[J]. JACC，2019，
aspirin therapy in patients with type 2 diabetes and re- 74（10）：1376-1414.
duced glomerular filtration rate：subanalysis from the [25] PIGNONE M，ALBERTS MJ，COLWELL JA，et al. Aspi-
JPAD trial[J]. Diabetes Care，2011，34（2）：280-285. rin for primary prevention of cardiovascular events in peo-
[15] JARDINE MJ，NINOMIYA T，PERKOVIC V，et al. Aspi- ple with diabetes：a position statement of the American Di-
rin is beneficial in hypertensive patients with chronic kid- abetes Association，a scientific statement of the American
ney disease：a post-hoc subgroup analysis of a randomized Heart Association，and an expert consensus document of
controlled trial[J]. J Am Coll Cardiol，2010，56（12）： the American College of Cardiology Foundation[J]. Diabe-
956-965. tes Care，2010，33（6）：1395-1402.
[16] BAIGENT C，LANDRAY M，LEAPER C，et al. First Unit- （收稿日期：2019-12-26 修回日期：2020-04-05）
ed Kingdom heart and renal protection（UK-HARP- Ⅰ） （编辑：邹丽娟）
study：biochemical efficacy and safety of simvastatin and

·1510 · China Pharmacy 2020 Vol. 31 No. 12 中国药房 2020年第31卷第12期